Abstract Number: 0060 • ACR Convergence 2023
Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Background/Purpose: Autoantibody-antigen complex-driven formation of neutrophil extracellular traps (NETs) is a major contributing factor to the pathophysiology and clinical manifestations of many different autoimmune diseases…Abstract Number: 0158 • ACR Convergence 2023
Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes
Background/Purpose: We developed an electronic health record (EHR)-based patient-facing sidecar dashboard application to display RA outcomes, including disease activity, functional status, and pain scores over…Abstract Number: 0327 • ACR Convergence 2023
Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…Abstract Number: 0392 • ACR Convergence 2023
Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles
Background/Purpose: Despite the diagnostic contribution of Anti-CCP3.1 (cyclic citrillunated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third…Abstract Number: 0409 • ACR Convergence 2023
Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in…Abstract Number: 0426 • ACR Convergence 2023
The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi…Abstract Number: 0443 • ACR Convergence 2023
The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis
Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…Abstract Number: 0459 • ACR Convergence 2023
Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial
Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…Abstract Number: 0745 • ACR Convergence 2023
Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis
Background/Purpose: Radiographs are used to detect and monitor joint damage due to rheumatoid arthritis (RA).Scoring methods such as the Sharp van der Heijde tool (SVH)…Abstract Number: 0806 • ACR Convergence 2023
Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Background/Purpose: To achieve optimal health outcomes, people with rheumatoid arthritis (RA) need to know their symptom patterns and be able to practice self-care activities. With…Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…Abstract Number: 1015 • ACR Convergence 2023
Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…Abstract Number: 1257 • ACR Convergence 2023
The Psychological Experience of Work for People with Inflammatory Arthritis (IA)
Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…Abstract Number: 1292 • ACR Convergence 2023
Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD
Background/Purpose: Lipid metabolism impacts immune cell plasticity, activation, differentiation, and function, making the analysis of the lipidomic profile crucial in understanding chronic inflammatory diseases like…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 188
- Next Page »